Atossa Hires Two Clinical Directors for Breast Cancer and Rare Disease Programs
Atossa appointed Dr. Kathy Puyana Theall as Breast Oncology Director and Dr. Adebola Giwa as Rare Diseases Director to bolster its clinical development organization and support key trials for (Z)-Endoxifen in oncology and rare disease indications. Their expertise in oncology, global trial execution and regulatory approvals will accelerate (Z)-Endoxifen’s breast cancer, McCune-Albright syndrome and Duchenne programs.
1. Strategic Clinical Leadership Appointments
Atossa appointed Dr. Kathy Puyana Theall as Breast Oncology Director and Dr. Adebola Giwa as Rare Diseases Director to bolster its clinical development organization and support key trials for (Z)-Endoxifen in oncology and rare disease indications.
2. Expertise of Dr. Kathy Puyana Theall
Dr. Theall is a board-certified medical oncologist with over 24 years of experience, who led FDA approval of elacestrant and advanced palbociclib through global trials; she will guide breast cancer program strategy and regulatory interactions.
3. Expertise of Dr. Adebola Giwa
Dr. Giwa is a board-certified pediatric endocrinologist with 15 years in academic medicine and biopharma, having led global trial design and safety oversight at Maze Therapeutics and Ascendis Pharma; he will steer rare disease programs including McCune-Albright syndrome and Duchenne muscular dystrophy.
4. Pipeline Advancement and Next Steps
These appointments position Atossa to accelerate clinical execution and regulatory filings for (Z)-Endoxifen across breast cancer, McCune-Albright syndrome and Duchenne muscular dystrophy, targeting data readouts and submissions in the coming months.